Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents
Benzamides
Blood Cell Count
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance
Female
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate
Leukemia, Myeloid, Accelerated Phase
Male
Middle Aged
Mutation
Piperazines
Protein-Tyrosine Kinases
Pyrimidines
Safety

authors with profiles

Richard A. Larson